Juliane Manitz

639 total citations
26 papers, 406 citations indexed

About

Juliane Manitz is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Juliane Manitz has authored 26 papers receiving a total of 406 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 7 papers in Surgery. Recurrent topics in Juliane Manitz's work include Cancer Immunotherapy and Biomarkers (9 papers), Bladder and Urothelial Cancer Treatments (7 papers) and Lung Cancer Treatments and Mutations (6 papers). Juliane Manitz is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Bladder and Urothelial Cancer Treatments (7 papers) and Lung Cancer Treatments and Mutations (6 papers). Juliane Manitz collaborates with scholars based in Germany, United States and United Kingdom. Juliane Manitz's co-authors include Helmut Küchenhoff, Markus Bühner, Kerstin Hermelink, Michael Untch, Michael P. Lux, Karin Münzel, Ingo Bauerfeind, Veronika Fensterer, Thomas Kneib and James L. Gulley and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

Juliane Manitz

25 papers receiving 397 citations

Peers

Countries citing papers authored by Juliane Manitz

Since Specialization

Citations

This map shows the geographic impact of Juliane Manitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juliane Manitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juliane Manitz more than expected).

Fields of papers citing papers by Juliane Manitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juliane Manitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juliane Manitz. The network helps show where Juliane Manitz may publish in the future.

Co-authorship network of co-authors of Juliane Manitz

This figure shows the co-authorship network connecting the top 25 collaborators of Juliane Manitz. A scholar is included among the top collaborators of Juliane Manitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juliane Manitz. Juliane Manitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients 2025 ·ESMO Open ·Shilpa Gupta, Miguel Á. Climent Durán, (unknown), (unknown), (unknown), (unknown), Howard Gurney, Norihiko Tsuchiya, Daniel P. Petrylak, Yoshihiko Tomita, (unknown), Juliane Manitz, (unknown), Justin Hoffman, (unknown), (unknown)	2
2	Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial 2025 ·European Urology Oncology ·Petros Grivas, Jeanny B. Aragon‐Ching, Joaquim Bellmunt, Yohann Loriot, Miguel Á. Climent Durán, Srikala S. Sridhar, Po‐Jung Su, Se Hoon Park, Evgeny Kopyltsov, Yoshiaki Yamamoto, (unknown), (unknown), (unknown), Juliane Manitz, Mairead Kearney, Michael Schlichting, Thomas Powles	0
3	Avelumab first‐line maintenance in advanced urothelial carcinoma: Complete screening for prognostic and predictive factors using machine learning in the JAVELIN Bladder 100 phase 3 trial 2024 ·Cancer Medicine ·Juliane Manitz, Aslihan Gerhold‐Ay, Pascal J. Kieslich, Parantu K. Shah, (unknown), (unknown)	1
4	Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival 2022 ·Journal for ImmunoTherapy of Cancer ·Juliane Manitz, Sandra P. D’Angelo, Andrea B. Apolo, S. Peter Eggleton, Marcis Bajars, Oliver Bohnsack, James L. Gulley	24
5	Sensor-based localization of epidemic sources on human mobility networks 2021 ·PLoS Computational Biology ·(unknown), Juliane Manitz, Enrico Bertuzzo, Eric D. Kolaczyk	3
6	Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial 2021 ·Lung Cancer ·Keunchil Park, Mustafa Özgüroğlu, Johan Vansteenkiste, David R. Spigel, James C. Yang, Marcis Bajars, Mary Ruisi, Juliane Manitz, Fabrice Barlesi	5
7	Estimands for overall survival in clinical trials with treatment switching in oncology 2021 ·Pharmaceutical Statistics ·Juliane Manitz, (unknown), Hannes Buchner, (unknown), Evgeny Degtyarev, Jyotirmoy Dey, Vincent Haddad, (unknown), Emily J. Martin, (unknown), Kaspar Rufibach, Yue Shentu, Viktoriya Stalbovskaya, Rui Tang, (unknown), (unknown)	16
8	Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab 2021 ·CPT Pharmacometrics & Systems Pharmacology ·Nadia Terranova, Jonathan French, Haiqing Dai, (unknown), Akash Khandelwal, Ana Ruiz-Garcı́a, Juliane Manitz, Anja von Heydebreck, Mary Ruisi, Kevin M. Chin, Pascal Girard, Karthik Venkatakrishnan	22
9	Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC) 2019 ·Annals of Oncology ·Fabrice Barlési, Mustafa Özgüroğlu, Johan Vansteenkiste, David R. Spigel, J.C.-H. Yang, Marcis Bajars, Mary Ruisi, Juliane Manitz, (unknown)	3
10	Avelumab treatment in metastatic urothelial carcinoma: Association between early response and durable outcomes in the phase Ib JAVELIN Solid Tumor Study. 2019 ·Journal of Clinical Oncology ·Manish R. Patel, James L. Gulley, Keun‐Wook Lee, Jeffrey R. Infante, Juliane Manitz, Vijay Kasturi, Hao Zhang, Galit Rosen, Andrea B. Apolo	1
11	Association of efficacy and adverse events of special interest of avelumab in the JAVELIN solid tumor and JAVELIN Merkel 200 trials. 2018 ·Journal of Clinical Oncology ·Karen Kelly, Juliane Manitz, Manish R. Patel, Anja H. Loos, Arthur Allignol, Vikram K. Chand, Vijay Kasturi, Kevin M. Chin, (unknown), Hao Zhang, Anja von Heydebreck, James L. Gulley	1
12	Humidification mitigates acute mucosal toxicity during radiotherapy when factoring volumetric parameters. Trans Tasman Radiation Oncology Group (TROG) RadioHUM 07.03 substudy 2017 ·Oral Oncology ·Andrew Macann, Fariza Fauzi, John B. Simpson, Giuseppe Sasso, Hedley Krawitz, Carol Fraser‐Browne, Juliane Manitz, Andrea Raith	6
13	Pathway-Based Kernel Boosting for the Analysis of Genome-Wide Association Studies 2017 ·Computational and Mathematical Methods in Medicine ·(unknown), Juliane Manitz, (unknown), Christopher I. Amos, Angela Risch, Jenny Chang‐Claude, Heinz‐Erich Wichmann, Thomas Kneib, Heike Bickeböller, Benjamin Hofner	5
14	Epidemiological and Ecological Characterization of the EHEC O104:H4 Outbreak in Hamburg, Germany, 2011 2016 ·PLoS ONE ·(unknown), Juliane Manitz, (unknown), G Fell, Thomas Kneib, (unknown)	9
15	Behavioral studies on the use of open water basins by American mink (Neovison vison) 2016 ·Journal of Veterinary Behavior ·(unknown), Shana Bergmann, Juliane Manitz, Helmut Küchenhoff, Michael Erhard, Elke Rauch	1
16	Origin Detection During Food-borne Disease Outbreaks - A Case Study of the 2011 EHEC/HUS Outbreak in Germany 2014 ·PLoS Currents ·Juliane Manitz, Thomas Kneib, Martin Schlather, Dirk Helbing, Dirk Brockmann	21
17	A Network-Based Kernel Machine Test for the Identification of Risk Pathways in Genome-Wide Association Studies 2013 ·Human Heredity ·Saskia Freytag, Juliane Manitz, Martin Schlather, Thomas Kneib, Christopher I. Amos, Angela Risch, Jenny Chang‐Claude, Joachim Heinrich, Heike Bickeböller	11
18	Bayesian outbreak detection algorithm for monitoring reported cases of campylobacteriosis in Germany 2013 ·Biometrical Journal ·Juliane Manitz, Michael Höhle	18
19	Prevalence of Anaplasma phagocytophilum in Ixodes ricinus in Bavarian public parks, Germany 2011 ·Ticks and Tick-borne Diseases ·(unknown), Kurt Pfister, H.-J. Reulen, Monia Mahling, Juliane Manitz, Claudia Thiel, Cornelia Silaghi	55
20	Two different sides of ‘chemobrain’: determinants and nondeterminants of self‐perceived cognitive dysfunction in a prospective, randomized, multicenter study 2010 ·Psycho-Oncology ·Kerstin Hermelink, Helmut Küchenhoff, Michael Untch, Ingo Bauerfeind, Michael P. Lux, Markus Bühner, Juliane Manitz, Veronika Fensterer, Karin Münzel	106

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact